Malignant b cell CD5 membrane phenotype and b cell colony growth in vivo and in vitro in patients with b-chronic lymphocytic leukemia: Analysis with clinical parameters

Ingrid Hings, Neil Elliot Kay, Erik Ranheim, Chris Seroogy, Robert E. Parson

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Chronic lymphocytic leukemia (CLL), despite an overall good prognosis, has a subgroup of patients with more rapid, aggressive disease. In an attempt to generate additional information about the B cell clones in B-CLL which could be used as predictive parameters, we analysed CD5 membrane phenotype and B cell colony growth in 29 B-CLL patients. CD5, a 67-kd glycoprotein, has been reported to be a consistent feature of the malignant B cell membrane phenotype in CLL. We used an in vitro B cell colony assay to study the in vitro growth, differentiation, and cell surface properties of CLL B cells. Finally, a variety of standard clinical parameters were collated for each patient. Monoclonal antibodies to both CD5 and CD 19 (pan B cell marker) were used to perform 2-color flow cytometry on freshly purified CLL B cells and on CLL B cells harvested after 7 days of in vitro culture. We demonstrate here that CLL B cells are heterogeneous with respect to their expression of CD5, and that this expression is not fixed but may vary both in vivo and in vitro. In vitro growth potential, as measured by the B cell colony assay, was also heterogeneous with three subgroups defined as low growth (<10 colonies), intermediate (10-100 colonies) and high growth (>100 colonies). Furthermore a T cell conditioned medium was not found to be a requirement for in vitro colony growth in the majority of CLL B cells. In addition, we evaluated the potential correlation of B cell CD5 phenotype or B cell colony growth on standard clinical parameters. A correlation between high CD5 expression (>85% CD5 positive) and lymphocyte doubling time less than 12 months and treatment within six months was detected. This study emphasizes that additional information regarding the biology of the malignant CLL B cell will generate new parameters that can be used to help predict the clinical course of B-CLL.

Original languageEnglish (US)
Pages (from-to)59-67
Number of pages9
JournalLeukemia and Lymphoma
Volume12
Issue number1-2
DOIs
StatePublished - 1993
Externally publishedYes

Fingerprint

B-Cell Chronic Lymphocytic Leukemia
Cell Membrane
Phenotype
B-Lymphocytes
Growth
In Vitro Techniques
Surface Properties
Conditioned Culture Medium
Cell Differentiation
Glycoproteins
Flow Cytometry
Clone Cells
Color
Monoclonal Antibodies
Lymphocytes
T-Lymphocytes

Keywords

  • B-CLL
  • CD5 B cell colony growth
  • Clinical parameters

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Malignant b cell CD5 membrane phenotype and b cell colony growth in vivo and in vitro in patients with b-chronic lymphocytic leukemia : Analysis with clinical parameters. / Hings, Ingrid; Kay, Neil Elliot; Ranheim, Erik; Seroogy, Chris; Parson, Robert E.

In: Leukemia and Lymphoma, Vol. 12, No. 1-2, 1993, p. 59-67.

Research output: Contribution to journalArticle

@article{0e2f502f396a4436a9eb12420a4352ed,
title = "Malignant b cell CD5 membrane phenotype and b cell colony growth in vivo and in vitro in patients with b-chronic lymphocytic leukemia: Analysis with clinical parameters",
abstract = "Chronic lymphocytic leukemia (CLL), despite an overall good prognosis, has a subgroup of patients with more rapid, aggressive disease. In an attempt to generate additional information about the B cell clones in B-CLL which could be used as predictive parameters, we analysed CD5 membrane phenotype and B cell colony growth in 29 B-CLL patients. CD5, a 67-kd glycoprotein, has been reported to be a consistent feature of the malignant B cell membrane phenotype in CLL. We used an in vitro B cell colony assay to study the in vitro growth, differentiation, and cell surface properties of CLL B cells. Finally, a variety of standard clinical parameters were collated for each patient. Monoclonal antibodies to both CD5 and CD 19 (pan B cell marker) were used to perform 2-color flow cytometry on freshly purified CLL B cells and on CLL B cells harvested after 7 days of in vitro culture. We demonstrate here that CLL B cells are heterogeneous with respect to their expression of CD5, and that this expression is not fixed but may vary both in vivo and in vitro. In vitro growth potential, as measured by the B cell colony assay, was also heterogeneous with three subgroups defined as low growth (<10 colonies), intermediate (10-100 colonies) and high growth (>100 colonies). Furthermore a T cell conditioned medium was not found to be a requirement for in vitro colony growth in the majority of CLL B cells. In addition, we evaluated the potential correlation of B cell CD5 phenotype or B cell colony growth on standard clinical parameters. A correlation between high CD5 expression (>85{\%} CD5 positive) and lymphocyte doubling time less than 12 months and treatment within six months was detected. This study emphasizes that additional information regarding the biology of the malignant CLL B cell will generate new parameters that can be used to help predict the clinical course of B-CLL.",
keywords = "B-CLL, CD5 B cell colony growth, Clinical parameters",
author = "Ingrid Hings and Kay, {Neil Elliot} and Erik Ranheim and Chris Seroogy and Parson, {Robert E.}",
year = "1993",
doi = "10.3109/10428199309059572",
language = "English (US)",
volume = "12",
pages = "59--67",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "1-2",

}

TY - JOUR

T1 - Malignant b cell CD5 membrane phenotype and b cell colony growth in vivo and in vitro in patients with b-chronic lymphocytic leukemia

T2 - Analysis with clinical parameters

AU - Hings, Ingrid

AU - Kay, Neil Elliot

AU - Ranheim, Erik

AU - Seroogy, Chris

AU - Parson, Robert E.

PY - 1993

Y1 - 1993

N2 - Chronic lymphocytic leukemia (CLL), despite an overall good prognosis, has a subgroup of patients with more rapid, aggressive disease. In an attempt to generate additional information about the B cell clones in B-CLL which could be used as predictive parameters, we analysed CD5 membrane phenotype and B cell colony growth in 29 B-CLL patients. CD5, a 67-kd glycoprotein, has been reported to be a consistent feature of the malignant B cell membrane phenotype in CLL. We used an in vitro B cell colony assay to study the in vitro growth, differentiation, and cell surface properties of CLL B cells. Finally, a variety of standard clinical parameters were collated for each patient. Monoclonal antibodies to both CD5 and CD 19 (pan B cell marker) were used to perform 2-color flow cytometry on freshly purified CLL B cells and on CLL B cells harvested after 7 days of in vitro culture. We demonstrate here that CLL B cells are heterogeneous with respect to their expression of CD5, and that this expression is not fixed but may vary both in vivo and in vitro. In vitro growth potential, as measured by the B cell colony assay, was also heterogeneous with three subgroups defined as low growth (<10 colonies), intermediate (10-100 colonies) and high growth (>100 colonies). Furthermore a T cell conditioned medium was not found to be a requirement for in vitro colony growth in the majority of CLL B cells. In addition, we evaluated the potential correlation of B cell CD5 phenotype or B cell colony growth on standard clinical parameters. A correlation between high CD5 expression (>85% CD5 positive) and lymphocyte doubling time less than 12 months and treatment within six months was detected. This study emphasizes that additional information regarding the biology of the malignant CLL B cell will generate new parameters that can be used to help predict the clinical course of B-CLL.

AB - Chronic lymphocytic leukemia (CLL), despite an overall good prognosis, has a subgroup of patients with more rapid, aggressive disease. In an attempt to generate additional information about the B cell clones in B-CLL which could be used as predictive parameters, we analysed CD5 membrane phenotype and B cell colony growth in 29 B-CLL patients. CD5, a 67-kd glycoprotein, has been reported to be a consistent feature of the malignant B cell membrane phenotype in CLL. We used an in vitro B cell colony assay to study the in vitro growth, differentiation, and cell surface properties of CLL B cells. Finally, a variety of standard clinical parameters were collated for each patient. Monoclonal antibodies to both CD5 and CD 19 (pan B cell marker) were used to perform 2-color flow cytometry on freshly purified CLL B cells and on CLL B cells harvested after 7 days of in vitro culture. We demonstrate here that CLL B cells are heterogeneous with respect to their expression of CD5, and that this expression is not fixed but may vary both in vivo and in vitro. In vitro growth potential, as measured by the B cell colony assay, was also heterogeneous with three subgroups defined as low growth (<10 colonies), intermediate (10-100 colonies) and high growth (>100 colonies). Furthermore a T cell conditioned medium was not found to be a requirement for in vitro colony growth in the majority of CLL B cells. In addition, we evaluated the potential correlation of B cell CD5 phenotype or B cell colony growth on standard clinical parameters. A correlation between high CD5 expression (>85% CD5 positive) and lymphocyte doubling time less than 12 months and treatment within six months was detected. This study emphasizes that additional information regarding the biology of the malignant CLL B cell will generate new parameters that can be used to help predict the clinical course of B-CLL.

KW - B-CLL

KW - CD5 B cell colony growth

KW - Clinical parameters

UR - http://www.scopus.com/inward/record.url?scp=0027742511&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027742511&partnerID=8YFLogxK

U2 - 10.3109/10428199309059572

DO - 10.3109/10428199309059572

M3 - Article

C2 - 7512855

AN - SCOPUS:0027742511

VL - 12

SP - 59

EP - 67

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 1-2

ER -